Myelodysplastic syndromes (MDS) often require frequent blood transfusions for anemia, which can lead to iron overload. Over time, extra iron can damage organs throughout the body. Underlying MDS ...

Agent Orange, the herbicide used in the Vietnam War, had not been linked to MDS blood cancers. A new study does that, and could help veterans get help.

A Servier Pharmaceuticals drug acquired as part of a $1.8 billion deal has won an additional FDA approval as a treatment for a rare type of blood cancer carrying a specific mutation. The regulatory ...

Reblozyl treatment in patients with anemia from lower-risk myelodysplastic syndromes achieved a greater independence from red blood cell transfusions compared with treatment with epoetin alfa.

Myelodysplastic syndromes (MDS) can damage bone marrow, lowering red blood cells and platelets. Transfusions replace missing cells to manage anemia or thrombocytopenia. Up to 9 in 10 people with MDS ...

WASHINGTON — Vietnam War veterans exposed to Agent Orange have a higher risk of developing a rare blood cancer that develops slowly over decades, according to a new study that for the first time links ...

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) This pivotal prospective study ...

Scientists from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an AI system that recognizes and characterizes white and red blood cells in microscopic ...

Low-dose Revlimid delayed transfusion dependency and improved treatment response rates in non-transfusion dependent MDS patients. Revlimid reduced the risk of transfusion dependency by 69.8% compared ...

Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). This is an ASCO Meeting Abstract from ...